Fresenius Signs Largest-Ever Biosimilar Deal With WuXi Biologics; US Ban Decision Due in Six Weeks

0 points · first seen 20h ago · 1 outlet · 0 comments

Fresenius WuXi Biologics biosimilar deal is the largest ever signed: 37 drug candidates targeting $414 billion in annual revenues, arriving six weeks before the US Office of Management and Budget publishes its BIOSECURE Act biotechnology company-of-concern list, a ruling that could restrict WuXi Biologics from US government contracts. — Tech Times

save

· share to X · Bluesky · copy link